Navigation Links
Polaris Group Appoints Robert E. Hoffman as Chief Financial Officer
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- Polaris Group today announced the appointment of Robert E. Hoffman as chief financial officer.

Hoffman has joined Polaris from Arena Pharmaceuticals Inc., where he held senior financial positions for more than 13 years. Most recently, Hoffman was vice president of finance and chief financial officer. In his leadership roles, Hoffman contributed to the success of Arena's initial public offering in 2000 and other equity, debt and collaborative  transactions that totaled nearly $1.5 billion as Arena built a pipeline of drug candidates and completed a Phase 3 pivotal program for its lead candidate.

"Robert brings extensive financial management experience from a public, late-stage development company to Polaris Group at a pivotal time," said Bor-Wen Wu, Ph.D., president and chief executive officer of Polaris Group. "We are moving our lead project, ADI-PEG 20, into a Phase 3 trial in hepatocellular carcinoma as well as advancing multiple Phase 2 trials in other cancer types. In line with our clinical progress, we are expanding our management team as Polaris transforms into a late-stage clinical development company."

Hoffman currently serves as a member of the Financial Accounting Standards Board's small business advisory committee and the steering committee of the Association of Bioscience Financial Officers. In addition, he is a member and former president of the San Diego chapter of Financial Executives International and a director of the charitable organization Day For Change. Hoffman earned a bachelor's degree in business administration from St. Bonaventure University.

"I am excited about the opportunity to participate in Polaris' transformation into a late-stage company," said Hoffman. "Lead project ADI-PEG 20 represents a significant opportunity in the treatment of many cancer types. I look forward to working with the Polaris team to advance this promising drug candidate through its final stages of clinical development."  

About ADI-PEG 20A key metabolic difference between some cancer cells and healthy cells is their dependence on the external supply of certain amino acids for survival and growth. ADI-PEG 20 is a pegylated form of arginine deiminase, an enzyme that depletes circulating arginine, which suppresses tumor cell growth while leaving healthy cells unharmed. ADI-PEG 20 has completed Phase 2 clinical trials in hepatocellular carcinoma (HCC) and in metastatic melanoma and is currently being investigated in Phase 2 trials in small cell lung cancer and in mesothelioma patients.

About Polaris GroupPolaris Group is a privately held, multinational biopharmaceutical company that specializes in the research and development of protein drugs to treat cancer and other debilitating diseases. The company's lead therapeutic, ADI-PEG 20, is advancing into a pivotal Phase 3 trial for hepatocellular carcinoma. Polaris is also investigating ADI-PEG 20 as a treatment for other arginine-dependent cancers, such as prostate cancer, leukemia, lymphoma, sarcoma and pancreatic cancer. In addition to the ADI-PEG 20 project, Polaris is researching and developing other biotherapeutic agents and has a small molecule drug program that utilizes rational structure-based approach to design novel compounds that inhibit the biological function of cancer-related protein targets.

For additional information please visit www.polarispharma.comMedia Contacts:Heidi Chokeir, Ph.D.Russo Partners(619) 528-2217(858) 380-6584heidi.chokeir@russopartnersllc.comJohn Bomalaski, M.D.Polaris Group(858) 452-6688, ext. 114jbomalaski@polarispharma.com
'/>"/>

SOURCE Polaris Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Home Medical Equipment Group Supports Bipartisan Bill to Repeal the Controversial Medicare Competitive Bidding Program for Homecare
2. Southern Home Medical Equipment Engages Northern Virginia Based Waterford Holdings Group to Evaluate and Consider Acquisition Candidates in the Mid-Atlantic Area
3. LaVoie Group Wins Gold Mercury Award For Medical Device Company, Alphatec Spine
4. LaVoie Group Wins Two Mercury Excellence Awards
5. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
6. Software Development Firms New Intellectual Property Group, Blue Horseshoe IP Creates Solutions to Help Customers Optimize Supply Chain
7. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
8. Rottenstein Law Group Applauds New Efforts of U.S. FDA to Look More Carefully at Metal-on-Metal Implants After DePuy Recall
9. PCMA: Anti-Fraud Group Spotlights Policies that Promote Health Care Fraud and Abuse
10. New Image Global, Inc. Partners With Limbs For U, Charitable Service Group to Provide Prosthetic Limbs in the Dominican Republic
11. Deb Group Introduces First Real-time Hand Hygiene Group Monitoring System Based on World Health Organization Guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... BURLINGAME, Calif. , Feb. 11, 2016  NOIT™ ... announced a special "Gift of Change" campaign to assist ... units. For every such unit sold between February 10, ... a unit to a needy family. The NOIT is ... helping non/limited-verbal autistic individuals develop language skills. ...
(Date:2/11/2016)... Ore. , Feb. 11, 2016 Wellpartner, ... announce the acquisition of SolutionsRx, a full-service 340B company ... Along with providing traditional contract pharmacy services, SolutionsRx also ... clients in navigating the complex 340B regulatory environment. ... --> James R. Love , CEO of ...
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions ... Transformational M&A achieved through NPS and Dyax acquisitions and the ... M&A achieved through NPS and Dyax acquisitions and the announced ... with most robust pipeline in Shire , s ... most robust pipeline in Shire , s history ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dermatology and women’s health, is pleased to announce the promotions of Allison Kelly ... sales team, Steve Catone to executive vice president of North American capital sales, ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... unparalleled clinical decision support technology, with highly adaptable algorithms, has been updated to ... patient has signs and symptoms consistent with Zikas and a travel history to ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... J.R. Garrett Esq. as General Counsel. Garrett will focus on contract negotiations, corporate ... audits, privacy and security law, and best practices in data breaches for the ...
(Date:2/11/2016)... ... ... Colorado spine surgeon, Donald Corenman, MD, DC has been selected ... 2016 . The list consists of spine surgeons across the country nominated by their ... the importance of clinical excellence; he has been awarded the Patient’s Choice Award, Compassionate ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance ... involvement program, introduces a new charity campaign to raise funds for Ronald McDonald ... accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally ...
Breaking Medicine News(10 mins):